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Purpose: The purpose of this study was to measure health-care resource utilization and costs in treatment-
adherent, previously seizure-free patients with epilepsy who were treated in the inpatient/emergency room
(ER) setting for new-onset seizures, compared with matched controls.
Methods: The study used a retrospective case/control study design using administrative claims from the IMS
PharMetrics™ database.We identiﬁed adult patientswith epilepsywith 1+ER visit/hospitalizationwith primary
diagnosis of epilepsy between 1/1/2006 and 3/31/2011, preceded by 6 months of seizure-free activity and anti-
epileptic drug (AED) treatment adherence (≥80% of days covered by any AED); the ﬁrst observed seizure deﬁned
the “breakthrough” seizure/index event. Treatment-adherent patientswith epilepsywithout any ER/hospital ad-
mission for seizures served as controls: an outpatient epilepsy-related medical claim within the selection win-
dow was chosen at random as the index date. The following were continuous enrollment requirements for all
patients: ≥12-month pre- and ≥6-month postindex. Each case matched 1:1 to a control using propensity score
matching. All-cause and epilepsy-related (epilepsy/convulsion diagnosis, AED pharmacy) resource utilization
and unadjusted and adjusted direct health-care costs (per person, 2012 US dollars (USD)) were assessed in a
6-month follow-up period.
Principal results: There were 5729 cases and 14,437 controls eligible. The ﬁnal sample comprised 5279 matched
case/control pairs. In unadjusted analyses, matched cases had signiﬁcantly higher rates of all-cause hospitaliza-
tion and ER visits compared to controls and signiﬁcantly higher total all-cause direct health-care costs (median
$12,714 vs. $5095, p b 0.001) and total epilepsy-related costs among cases vs. controls (median $7293 vs. $1712,
p b 0.001), driven by higher inpatient costs. Among cases, costs increased with each subsequent seizure (driven
by inpatient costs). Cases had 2.3 times higher adjusted all-cause costs and 8.1 times higher adjusted epilepsy-
related costs than controls (both p b 0.001).
Conclusion: Inpatient/ER-treated breakthrough seizures occurred among 28.4% of our treatment-adherent study
sample and were associated with signiﬁcant incremental health-care utilization and costs, primarily driven by
hospitalizations. Our ﬁndings suggest the need for better seizure control via optimal patient management and
the use of effective AED therapy, which can potentially lower health-care costs.© 2015 Elsevier Inc. All rights reserved.1. Introduction
Epilepsy is a chronic brain disorder characterized by recurrent
seizures caused by abnormal neuronal activity, impacting more than
2.3 million adults in the US [1]. Therapeutic options for better seizurey room; USD, US dollars; GABA,
ion; HIPAA, Health Insurance
f days covered; CCI, Charlson
ctitioner; GPI, general product
nal medicine; POS, partial onset
.control include antiepileptic drug (AED) therapies such as sodium chan-
nel blockers and gamma-aminobutyric acid (GABA) enhancers, and in
the case of drug-resistant epilepsy, surgical therapies such as vagal
nerve stimulation (VNS) and focal resection [2,3]. Treatment choice is
primarily based on the efﬁcacy of an AED for a speciﬁc seizure type,
but other factors such as tolerability, age, sex, and comorbidities are
also important to consider [4,5].
Approximately two-thirds of newly diagnosedpatientswith epilepsy
will become seizure-free with AED therapy (typically deﬁned as
seizure-free for ≥1 year), and for most, seizure control will be achieved
with the use of their ﬁrst or second AED regimen [2]. However, at least
one-third of patients may continue to experience seizures, sometimes
referred to as “breakthrough seizures”. Breakthrough seizures have
been described in the literature as seizures that happen suddenly and
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clinical deﬁnition within guidelines is lacking [4,7–9]. Breakthrough
seizures are most often discussed as a potential consequence of a
change in AED, or nonadherence to prescribed AEDs; however, other
potential precipitants include onset of an infection, sleep deprivation,
severe emotional stress, and provocative environmental factors
such as ﬂashing lights or playing video games [6,10,11]. There can be
severe consequences of breakthrough seizures including risk of
accidents, fractures or head injuries, emergency room (ER) visits,
and hospitalization, as well as an associated increase in health-care
costs.
The economic burden of epilepsy is well established in the literature
[12]. Higher health-care costs have also been associated with increasing
number of seizures from initial epilepsy diagnosis [13]. Patients with re-
fractory epilepsy (deﬁned as use of ≥3 AEDs in a calendar year) have
been found to have higher costs compared to patients with well-
controlled epilepsy among patients with partial onset seizures (POS)
[14]. Patients with uncontrolled epilepsy (deﬁned as addition of an AED
to an existing regimen) have been found to have higher costs compared
to patients with stable epilepsy [15]. Patients with uncontrolled epilepsy
(deﬁned as ≥2 changes in AED therapy, followed by ≥1 epilepsy-related
ED visit/hospitalization within 1 year) have been found to have higher
costs compared to patients withwell-controlled seizures (no AED change
and no epilepsy-related ER visit/hospitalization) [16]. Additionally, one
study assessedpatientswho received epilepsy-related treatment in emer-
gent care settings after a period of AED adherence and seizure control and
found higher costs in the 6 months following the event compared to the
6 months prior [17].
The objective of this study was to evaluate the direct cost impact of
breakthrough seizures amongAED-adherent patients.We identiﬁed pa-
tients with epilepsy in a USmanaged care population with and without
evidence of a breakthrough seizure after a period of sustained control
and compared all-cause and epilepsy-related health-care resource
utilization and direct health-care costs between matched cohorts in
the 6-month follow-up period. Additionally, we evaluated the impact
of seizure frequency on all-cause health-care resource utilization and
direct costs among cases. These ﬁndings would help quantify the fre-
quency of breakthrough seizures as well as the direct clinical and
economic consequences caused by breakthrough seizures, currently
missing from existing literature.
2. Materials and methods
2.1. Data source
This retrospective database analysis utilized data from the IMS
LifeLink Health Plan Claims database (PharMetrics™), comprising fully
adjudicated medical and pharmaceutical claims for approximately 70
million unique patients from over 70 health plans across the US at the
time of the study. Enrollees represented include those covered by
employer-sponsored plans and government-sponsored but commer-
cially administered Medicaid and Medicare plans as well as individuals
purchasing coverage in the marketplace. Among payer types for all
enrollees, 79% have a commercial plan while 10% are self-insured. The
remaining 11% comprise Medicaid, Medicare Cost, Medicare Risk, or
State Child Health Insurance. The PharMetrics database is most
represented by the Midwest (34%) and South (31%), followed by the
Northeast (19%) and thenWest (16%). The database is overrepresented
by the Midwest and slightly underrepresented by the South and West:
compared to the 2010 US census, the US population was highest in
the South (37%), followed by the West (23%) and Midwest (22%),
and then the Northeast (18%) [18]. Records are representative of
the national, commercially insured population on demographic
measures, including age and gender. Data elements include patient
and plan type/enrollment, as well as inpatient and outpatient diagnoses
(in ICD-9-CM format) and services/procedures, and both retail andmail order prescription records. Allowed, charged, and paid amounts
are available for all services rendered as well as dates of service for
all claims. The data are longitudinal, with an average member
continuous enrollment period of more than two years, providing
complete data capture. Patient data are de-identiﬁed following
the Health Insurance Portability and Accountability Act (HIPAA);
therefore, this study was exempt from Institutional Review Board
review.2.2. Cohort selection
Medical and pharmacy claims were assessed to identify adult
(18+ years) cases and controls based on seizure activity within the
sample selection window (July 1, 2006 to March 31, 2011). Because
there is no single clinical deﬁnition or clinical diagnosis code for break-
through seizure, we developed our deﬁnition based on a review of
the literature and clinical input. We used our breakthrough seizure
deﬁnition as a proxy to identify the subset of patients who experience
breakthrough seizures and receive inpatient/ER care. Similar to two
studies by Zachry et al., our breakthrough seizure deﬁnition required
an epilepsy-related inpatient or ER admission following a combined
period of seizure control and AED adherence [17,19]. Breakthrough
seizures were identiﬁed as an ER or inpatient admission with a
primary diagnosis of epilepsy (ICD-9-CM code 345.x excluding 345.6
[infantile spasms]), occurring in patients who had no evidence of a
seizure and with ≥80% of days covered by any AED (proportion of days
covered (PDC)) during the 6-month preindex period (80% adherence
is a commonly usedmeasure of “good” adherencewithin the literature).
Patients meeting the criteria for a breakthrough seizure were identiﬁed
as cases. The ﬁrst seizure eligible as a breakthrough seizure within the
sample selection window was chosen as the index date for cases.
These requirements help provide conﬁdence that the observed break-
through seizure, occurring after a period of sustained seizure control
and medication adherence, more likely resulted due to AED inefﬁcacy
rather than nonadherence.
The control group consisted of patients with epilepsy who had no
evidence of a seizure in their entire available time within the database
andwhomet the sameAED adherence requirements as cases. A random
outpatient medical claim (i.e., physician or facility visit) containing a
primary diagnosis of epilepsy during the selectionwindowwas selected
as the index date for controls in order to help ensure that controls were
captured in all stages of the disease.
All patients were required to have ≥12-month preindex continuous
health plan enrollment with ≥1 epilepsy diagnosis within that period.
Patients were further required to have ≥6-month continuous health
plan enrollment postindex (the follow-up period). The continuous
health plan enrollment criteria were required to eliminate the impact of
insurance coverage interruptions and to ensure visibility into a patient's
health-care utilization and costs under his or her plan's coverage.
Patients with incomplete health plan data (e.g., Medicare Fee-for-
Service plan) were excluded.
Propensity score matching was utilized on the ﬁnal eligible sample
to control for demographic and clinical factors which may otherwise
impact resource utilization and costs, aside from the event of interest
(seizure activity resulting in ER/inpatient care). Propensity score
matching is a common regression modeling technique used in retro-
spective database analysis to adjust for differences between study
cohorts. After examining unadjusted baseline patient characteristics,
cases and controls were matched 1:1 using a “nearest neighbor”
approach, deﬁned by a minimal difference (e.g., b0.001) in the ﬁtted
probability of experiencing a breakthrough seizure on the following
characteristics: age group, gender (although not signiﬁcant), payer
type, physician specialty, and the following characteristics measured
over the 6-month preindex: Charlson Comorbidity Index, essential hy-
pertension, and all-cause health-care costs (in the 6-month preindex).
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Baseline clinical characteristics were calculated using medical and
pharmacy claims from the 6-month preindex period. The following
measures were evaluated over the 6-month follow-up period:
• Antiepileptic drug adherence was measured for matched cases and
controls using PDC. Proportion of days covered was measured until
the end of the last supply for the patient's index AED therapy over
the 6-month follow-up period. Proportion of days covered was calcu-
lated with the total number of days supplied for a patient's index AED
therapy as the numerator, and the number of days until the end of the
last supply as the denominator. Proportion of days covered was
capped at 100%; ≥80% PDC by any AED was considered adherent.
• All-cause and epilepsy-related health-care resource utilization and di-
rect health-care costs in the 6-month follow-up period were assessed
and compared between matched cases and controls. Health-care
service categories included outpatient pharmacy (retail and mail),
hospitalizations, ER visits (not resulting in hospital admission), and
outpatient care (physician visits/procedures).
○ Epilepsy related claims were inclusive of AED therapy and medical
claims with an epilepsy or convulsion diagnosis (ICD-9-CM 345.x,
780.3 in any position).
○ The number of unique AED medications was deﬁned at the class
level (anticonvulsants (miscellaneous), anticonvulsant combina-
tions, benzodiazepines, carbamates, GABA modulators, hydantoins,
succinimides, valproic acid) while the number of unique non-AED
medications was deﬁned at the therapeutic class level (i.e., 10-
digit GPI code).
○ Total costs consisted of both total outpatient pharmacy and total
medical care (inpatient, ER, outpatient) costs. Costs were reported
in 2012 US dollars (USD) as costs per patient and evaluated on a
per cohort member basis (inclusive of all patients whether they ex-
perienced utilization in a service category or not).
○ All-cause resource utilization and cost outcomes by seizure frequency
(1, 2, 3+ seizures) in the 6-month follow-up period were reported
descriptively among cases.
2.4. Statistical/analytical methods
Descriptive and summary statistics were reported. Independent sta-
tistical testing was used to evaluate differences: pairwise comparisons
(chi-square) for categorical measures and the Wilcoxon rank-sum test
conducted on the median for continuous measures. Generalized esti-
mating equation (GEE) models were developed to adjust all-cause and
epilepsy-related costs for baseline covariates. A p-value b 0.05 was con-
sidered statistically signiﬁcant. All analyses were conducted using SAS
version 9.1 (Cary, NC).
3. Results
3.1. Baseline demographic and clinical characteristics
A total of 20,166 patients met our initial selection criteria,
representing an occurrence of breakthrough seizures among 28.4%
(5729 cases; 14,436 controls) of our study population during the 5-
year study window. Prior to propensity score matching, cases and
controls were signiﬁcantly different (at p b 0.001) on a number of de-
mographic and clinical characteristics. Cases were signiﬁcantly younger
(mean age 42.1 and 44.8 years [median 43 vs. 47 years]), fewer were
commercially insured (74.1% and 80.7%) and more were Medicaid-
insured (9.2% vs. 4.0%), fewer had a CCI score of 0 (62.4% vs. 72.5%),
and fewer cases used 1 unique AED class in the 6-month preindex
(52.5% vs. 70.7%) (use of N1 unique AED class indicates either a switchor combination therapy of 2 or more AED classes); however, it is possi-
ble that patients using only 1 unique AED class switched or received
combination therapy of 2 different AEDs in the same class. Cases also
had higher 6-month preindex total all-cause health-care costs (mean
$14,663 vs. $7115 [median $6408 vs. $3276]).
Following 1:1 propensity score matching, the ﬁnal sample consisted
of 5279matched cases and 5279 matched controls who were similar in
baseline demographic and clinical characteristics (see Table 1). A few
signiﬁcant differences remained between cases and controls. Cases
used more unique AED classes in the 6-month preindex: 39.8% with 2
AED classes and 13.1% with 3+ AED classes, compared to 32.8% and
7.7% of controls, respectively (p b 0.0001). A number of AEDdrug classes
used in the 6-month preindex were more frequent among cases
compared to controls, including benzodiazepines (33.6% vs. 25.5%)
and hydantoins (26.5% vs. 21.2%, both p b 0.0001). Epilepsy diag-
nosis type on the index date was signiﬁcantly different, with
18.2% of cases with partial seizures compared to 32.3% of controls
and 61.6% and 41.3% with other epilepsy, respectively. Total all-
cause health-care costs in the 6-month preindex were slightly
though signiﬁcantly higher among cases (median $5954 vs. $5919,
p = 0.0485).
3.2. Adherence to AED treatment in the 6-month follow-up period
In the 6-month follow-up period, both cases and controls demon-
strated high rates of AED adherence (PDC on any AED), both with a
mean PDC of 92% and median of 100%.
3.3. Number of seizures in the 6-month follow-up period (cases)
Among matched cases, the vast majority (75.8%) experienced a sin-
gle seizure resulting in ER/inpatient care (i.e., the breakthrough seizure
experienced at index) in the follow-up period; 17.4% experienced 2 sei-
zures, and 6.8% experienced 3 or more seizures.
3.4. All-cause health-care resource utilization and costs in the 6-month
follow-up period
In the 6-month follow-up period, all-cause health-care resource use
was higher among matched cases compared to controls, and all-cause
health-care costs were signiﬁcantly higher among cases for almost all
of the services assessed (Fig. 1, Tables 2 and 3). The number of unique
AED classes used was similar between cases and controls (mean 1.9,
median 2.0 both). While cases had signiﬁcantly higher total outpatient
pharmacy costs and higher AED medication costs per person, controls
had signiﬁcantly higher total non-AED pharmacy costs per person
compared to cases. Cases experienced signiﬁcantly higher rates of all-
cause hospitalizations (60.5% vs. 9.1% with ≥1 hospitalization) and ER
visits (64.9% vs. 19.2% with ≥1 visit) compared to controls (both
p b 0.0001). Almost all patients had ≥1 outpatient physician ofﬁce
visit (any specialty). Amongpatientswith ≥1 outpatient physician ofﬁce
visit, cases had more visits per person compared to controls (mean 8.6
vs. 7.6 [median 6.0 vs. 5.0, p b 0.0001]).
Cases had higher mean total all-cause direct health-care costs per
person compared to controls ($23,821 vs. $9989 [median $12,714 vs.
$5095; p b 0.0001]). All-cause health-care costs were driven by inpa-
tient costs for cases (mean inpatient costs comprised 57% of mean
total costs for cases compared to 19% for controls). At the p b 0.0001
level, cases had higher mean total medical care costs, higher mean
inpatient costs, and higher mean ER costs per person.
Among cases, all-cause health-care resource utilization in the
6-month follow-up period progressively increased with number of
seizures (1, 2 and 3+) as did all-cause health-care costs (Fig. 1,
Tables 2 and 3) for almost all service categories assessed, including
hospitalizations, ER visits, outpatient visits, and VNS surgery. Mean
total costs per person doubled between patients with 1 and 2 seizures
Table 1
Patient baseline demographic and clinical characteristics.
Characteristic Matched controls
(N = 5279)
Matched cases
(N = 5279)
p-Valueb
Age at indexa
Mean (SD) 42.5 (14.7) 42.4 (15.0)
Median 43 44 0.4629
Gendera (n, %) 0.7535
Female 2972 56.3% 2988 56.6%
Male 2307 43.7% 2291 43.4%
Geographic region (n, %) 0.0156
Northeast 1023 19.4% 1096 20.8%
Midwest 1841 34.9% 1840 34.9%
South 1695 32.1% 1724 32.7%
West 720 13.6% 619 11.7%
Health plan type (n, %) 0.2394
PPO 3200 60.6% 3217 60.9%
HMO 1101 20.9% 1118 21.2%
Other 978 18.5% 944 17.9%
Payer typea (n, %) 0.4852
Commercial plan 4121 78.1% 4058 76.9%
Medicaid 329 6.2% 367 7.0%
Medicare risk 246 4.7% 267 5.1%
Self-insured 526 10.0% 531 10.1%
Unknown 57 1.1% 56 1.1%
Number of unique AED classes observed in 6-month preindex (n, %)a b .0001
1 AED class 3142 59.5% 2486 47.1%
2 AED classes 1729 32.8% 2101 39.8%
3+ AED classes 408 7.7% 692 13.1%
AED drug classes used in 6-month preindex (n, % [not mutually exclusive])
Anticonvulsants–misc 4306 81.6% 4523 85.7% b .0001
Benzodiazepines 1347 25.5% 1776 33.6% b .0001
Hydantoins 1119 21.2% 1397 26.5% b .0001
Valproic acid 957 18.1% 1004 19.0% 0.2395
Carbamates 52 1.0% 60 1.1% 0.4473
Succinimides 36 0.7% 39 0.7% 0.7281
GABA modulators 33 0.6% 36 0.7% 0.7171
Total days covered by any AEDc in 6-month preindex
Mean (SD) 174.01 (9.48) 174.47 (9.46)
Median 180.0 180.0 b .0001
Epilepsy diagnosis on the index date (n, %) b .0001
Generalized 1395 26.4% 1066 20.2%
Partial 1704 32.3% 959 18.2%
Other 2180 41.3% 3254 61.6%
Charlson Comorbidity Index (CCI) scorea
Mean (SD) 0.72 (1.30) 0.76 (1.38)
Median 0.0 0.0 0.4937
Frequent (≥10%) epilepsy-related comorbidities (n, % yes)
Depression 633 12.0% 755 14.3% 0.0004
Anxiety disorders 534 10.1% 591 11.2% 0.0722
Essential hypertensiona 1181 22.4% 1184 22.4% 0.9442
a Variable used in propensity score matching of cases and controls.
b Pairwise comparisons (chi-square) were used for categorical measures. The Wilcoxon rank-sum test was conducted on the median for continuous measures.
c A minimum of 144 days was required for study entry.
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with 2 and 3+ seizures ($35,569 and $52,320). Costs were pri-
marily driven by medical care and speciﬁcally by hospitaliza-
tions. Mean medical care costs increased with number of seizures
($15,149 to $48,284) and comprised 82% to 92% of mean total
health-care costs.60.5% 64.9%
9.1%
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Fig. 1. Total unadjusted health-care utilization: proportion with inpatient and ER visits, al3.5. Epilepsy-related resource utilization and costs in the 6-month
follow-up period
Epilepsy-related resource use in the 6-month follow-up period was
higher among matched cases compared to controls, and epilepsy-
related costs were signiﬁcantly higher for all services assessed (Fig. 1,9.2%
60.1%
76.5%
89.4%
57.4%
6.0%
ER Visits
All-Cause, Cases
All-Cause, Controls
All-Cause, Cases, 1 seizure
only
All-Cause, Cases, 2 seizures
All-Cause, Cases, 3+ seizures
Epilepsy-Related, Cases
Epilepsy-Related, Controls
l-cause and epilepsy-related, in the 6-month follow-up period for cases and controls.
Table 2
Total unadjusted all-cause health-care resource utilization for cases and controls in the 6-month follow-up period.
Matched controls and cases Number of seizures in 180-day postindex period
Matched controls
(N = 5279)
Matched cases
(N = 5279)
p-Valuea 1 Seizure
(N = 4002)
2 Seizures
(N = 919)
3+ Seizures
(N = 358)
Resource use
category per person
Mean Median SD Mean Median SD Mean Median SD Mean Median SD Mean Median SD
Outpatient prescription medications
Number of unique medications 7.4 6.0 5.6 8.0 7.0 5.8 b .0001 7.6 6.0 5.7 8.6 7.0 5.8 10.2 9.0 6.2
Number of unique AEDs 1.9 2.0 0.4 1.9 2.0 0.4 0.7766 1.8 2.0 0.4 1.9 2.0 0.4 1.9 2.0 0.3
Inpatient visits (all-cause hospitalizations)
Proportion of patients with 1+ hospitalization
(n, %)
481 9.1 3191 60.5 b .0001 2286 57.1 634 69.0 271 75.7
Number of visits 1.4 1.0 1.0 1.5 1.0 1.0 0.0006 1.3 1.0 0.8 1.9 2.0 1.1 2.8 3.0 1.7
Length of inpatient stay (days) 6.5 3.0 9.6 6.1 3.0 10.6 0.5929 5.5 3.0 8.3 7.2 4.0 14.3 6.7 3.0 11.7
ER visits
Proportion of patients with 1+ ER visit (n, %) 1013 19.2 3427 64.9 b .0001 2404 60.1 703 76.5 320 89.4
Number of visits 1.7 1.0 1.9 2.0 1.0 2.1 b .0001 1.7 1.0 1.9 2.3 2.0 1.6 4.0 3.0 3.1
Outpatient care
Proportion of patients with at least 1 ofﬁce
visit (any specialty) (n,%)
5165 97.8 5080 96.2 b .0001 3840 96.0 888 96.6 352 98.3
Number of ofﬁce visits 7.6 5.0 8.6 8.6 6.0 9.6 b .0001 8.2 5.0 9.3 9.6 7.0 10.5 10.6 8.0 10.6
Number of GP/FM/IM visits 1.1 1.0 1.3 1.6 1.0 1.8 b .0001 1.4 1.0 1.7 1.9 1.0 2.0 2.2 2.0 2.2
Number of neurologist visits 1.8 1.0 3.2 2.2 1.0 3.4 b .0001 2.0 1.0 3.0 2.5 1.0 4.1 3.3 2.0 4.9
Number of other specialist visits 4.7 2.0 7.3 4.9 2.0 8.2 0.7785 4.8 2.0 8.2 5.3 2.0 8.6 5.1 3.0 7.3
Received vagal nerve stimulation (VNS)
surgery (n,%)
107 2.0 172 3.3 b .0001 107 2.7 39 4.2 26 7.3
a Comparisons betweenmatched controls andmatched cases performedusing chi-square testing for categorical variables and theWilcoxon rank-sumtest on themedian for continuous
variables.
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(59.2% vs. 4.6%) or ER visit (57.4% vs. 6.0%) compared to few controls
(both p b 0.0001). Among cases and controls with ≥1 epilepsy-related
physician ofﬁce visit (84.4% and 85.2%), cases hadmore visits per person
compared to controls (mean 3.2 vs. 1.9 visits [median 2.0 vs. 1.0,
p b 0.0001]). Cases had signiﬁcantly higher mean total epilepsy-
related health-care costs per person compared to controls ($14,491 vs.
3215 [median $7293 vs. $1712, p b 0.0001]). Epilepsy-related health-
care costs were driven by inpatient costs for cases with mean inpatient
costs comprising 65% of total costs for cases and 14% for controls.
Conversely, outpatient AED pharmacy costs represented 54% of total
epilepsy-related health-care costs for controls and 15% for cases. CasesTable 3
Total unadjusted all-cause health-care costs for cases and controls in the 6-month follow-up p
Matched cases and controls
Cost (2012 USD) per person Matched controls
(N = 5279)
Matched cases
(N = 5279)
p-Valu
Mean Median SD Mean Median SD
Total all-cause direct
expenditures
9989 5095 18,932 23,821 12,714 38,028 b .000
Total outpatient pharmacy
expenditures
3440 2251 4308 3559 2518 4151 b .000
AED medications 1748 994 2232 2211 1451 2565 b .000
Non-AED medications 1692 520 3710 1348 400 3209 b .000
Total medical care
expenditures
6549 1787 17,550 20,262 9151 37,310 b .000
Inpatient 1927 0 11,756 13,631 3986 32,673 b .000
ER 265 0 1465 1105 363 2470 b .000
Outpatient care
Ofﬁce visits 761 418 1840 893 522 1988 b .000
Surgery 401 0 1481 428 0 2586 0.000
Ancillary services
Laboratory and
pathology
280 101 599 335 111 757 0.066
Radiology 668 8 2619 922 88 3588 b .000
Other ancillary
expenditures
2247 264 8428 2947 935 8411 b .000
a Comparisons between matched controls and matched cases performed using chi-square tehad highermeanmedical care costs, highermean inpatient costs, higher
mean ER costs, and higher outpatient AED pharmacy costs per person
(all p b 0.0001). Epilepsy-related costs represented 61% of total all-
cause costs for cases and 32% for controls.
3.6. Adjusted costs
After adjusting for baseline covariates in the GEEmodels, cases were
associated with 2.3 times higher all-cause costs and 8.1 times higher
epilepsy-related costs compared to controls in the 6-month follow-up
period (both p b 0.0001) (Table 5). The use of a single AED therapeutic
class in the 6-month preindex was associated with 28.4% lowereriod.
Number of seizures in 180-day postindex period
ea 1 Seizure
(N = 4002)
2 Seizures
(N = 919)
3+ Seizures
(N = 358)
Mean Median SD Mean Median SD Mean Median SD
1 18,574 10,816 26,659 35,569 18,897 53,706 52,320 31,095 67,230
1 3425 2355 4200 3957 3001 3838 4036 2934 4284
1 2087 1326 2509 2608 1969 2595 2581 1707 2953
1 1338 376 3319 1349 437 2829 1455 546 2852
1 15,149 7509 25,828 31,612 14,641 53,226 48,284 27,899 66,385
1 9436 2156 21,983 23,335 8434 48,092 35,623 14,528 59,113
1 830 216 2157 1550 726 2499 3036 1838 4111
1 808 481 1498 1157 623 3451 1166 748 1523
2 415 0 2541 373 0 1810 714 0 4244
9 311 104 741 381 123 810 488 210 780
1 754 68 2600 1450 180 5596 1452 262 5719
1 2595 764 7889 3368 1400 7721 5804 2404 13,605
sting for categorical variables and the Wilcoxon rank-sum tests on the median.
Table 4
Total unadjusted epilepsy-related health-care costs for cases and controls in the 6-month follow-up period.
Matched controls
(N = 5279)
Matched cases
(N = 5279)
p-Valuea
Cost (2012 USD) per person Mean Median SD Mean Median SD
Total epilepsy-related direct expenditures 3215 1712 5675 14,491 7293 26,924 b .0001
Total outpatient pharmacy expenditures
AED medications 1748 994 2232 2211 1451 2565 b .0001
Total medical care expenditures 1467 280 5143 12,280 4911 26,508 b .0001
Inpatient 452 0 3794 9446 932 24,878 b .0001
ER 58 0 740 787 181 1756 b .0001
Outpatient care
Ofﬁce visits 176 117 314 299 190 660 b .0001
Surgery 83 0 728 187 0 2346 0.0139
Ancillary services
Laboratory and pathology 83 0 251 138 0 346 b .0001
Radiology 117 0 632 338 0 1873 b .0001
Other ancillary expenditures 497 3 2960 1086 260 3287 b .0001
a Comparisons between matched controls and matched cases performed using chi-square testing for categorical variables and the Wilcoxon rank-sum tests on the median.
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use of 2 or more AED classes (both p b 0.0001). Several baseline comor-
bidities were signiﬁcantly associatedwith higher all-cause costs includ-
ing other pain and depression.
4. Discussion
Our analysis uncovered a substantial clinical and economic burden
among AED-adherent patients with epilepsy in the 6-month period fol-
lowing the ﬁrst ER/inpatient-treated breakthrough seizure (versus
matched controls). Despite consistent treatment with AEDs, patients
with breakthrough seizures utilized signiﬁcantly more resources and
had signiﬁcantly higher costs than patients without breakthrough
seizures, with double the mean total all-cause unadjusted direct
health-care costs per person and 4.5 times higher mean total epilepsy-
related health-care costs per person. Additionally, all-cause health-
care utilization and costs increased with each subsequent seizure.Table 5
Generalized estimating equation (GEE) regression models of all-cause costs and epilepsy-relat
Independent variablesa Parameter
estimate
Sta
err
Dependent variable: all-cause total health-care costs in the 6-month follow-up period
Cases vs. controls 0.836 0.0
Unique preindex AED classes (1 vs. 2+) −0.334 0.0
Geographic region: midwest vs. northeast 0.168 0.0
Geographic region: south vs. northeast 0.033 0.0
Geographic region: west vs. northeast 0.047 0.0
History of depression: yes vs. no 0.176 0.0
History of anxiety disorders: yes vs. no 0.006 0.0
History of psychosis/psychotic states: yes vs. no 0.123 0.0
History of behavioral problems (including aggression): yes vs. no −0.118 0.1
History of mental retardation: yes vs. no 0.390 0.1
History of migraine: yes vs. no 0.051 0.0
History of other pain: yes vs. no 0.343 0.0
Dependent variable: epilepsy-related total health-care costs in the 6-month follow-up period
Cases vs. controls 2.097 0.0
Unique preindex AED classes (1 vs. 2+) −0.372 0.0
Geographic region: midwest vs. northeast 0.244 0.0
Geographic region: south vs. northeast 0.026 0.0
Geographic region: west vs. northeast 0.278 0.1
History of depression: yes vs. no 0.129 0.0
History of anxiety disorders: yes vs. no −0.063 0.0
History of psychosis/psychotic states: yes vs. no −0.048 0.0
History of behavioral problems (including aggression): yes vs. no 0.145 0.2
History of mental retardation: yes vs. no 0.093 0.1
History of migraine: yes vs. no −0.025 0.0
History of other pain: yes vs. no 0.028 0.0
a Cases and controls were propensity score matched on age group, gender (although not sig
tension in the preindex period, and preindex health-care costs. Therefore, these characteristicsAdjusted analyses corroborated the unadjusted ﬁndings, and patients
with breakthrough seizures were associated with 2.3 times higher all-
cause costs and 8.1 times higher epilepsy-related costs compared to
controls.
In unadjusted analyses, the burden of breakthrough seizures was
primarily driven by inpatient costs, which represented 57% of total
costs for patients with breakthrough seizures compared to 19% for
controls. Epilepsy-related inpatient costs represented 69% and 24% of
all-cause inpatient costs for patients with breakthrough seizures vs.
controls, respectively, demonstrating the impact of epilepsy on inpa-
tient resource use and costs following a breakthrough seizure. Further,
epilepsy and convulsions accounted for more than 70% of the top inpa-
tient principal diagnoses for cases. More research is needed to under-
stand the cost drivers at the inpatient level and whether the increase
in inpatient costs is related tomanaging seizure activity or the potential
causes (e.g., malignancy or arteriovenous malformations) or conse-
quences (e.g., trauma) of the seizures.ed costs in the 6-month follow-up period.
ndard
or
95% Conﬁdence interval Exponentiated parameter
estimate
Lower limit Upper limit p-Value
3 0.77 0.90 b .0001 2.308
4 −0.40 −0.26 b .0001 0.716
5 0.08 0.26 0.000 1.182
5 −0.06 0.12 0.474 1.034
6 −0.07 0.16 0.433 1.048
5 0.08 0.27 0.000 1.193
5 −0.09 0.10 0.899 1.006
6 0.01 0.23 0.030 1.131
3 −0.37 0.13 0.355 0.889
2 0.16 0.62 0.001 1.477
5 −0.04 0.14 0.278 1.052
6 0.23 0.46 b .0001 1.410
6 1.99 2.21 b .0001 8.138
6 −0.49 −0.26 b .0001 0.689
7 0.11 0.37 0.000 1.276
8 −0.13 0.18 0.736 1.027
0 0.09 0.47 0.005 1.321
8 −0.02 0.28 0.089 1.138
8 −0.23 0.10 0.442 0.939
9 −0.22 0.12 0.584 0.953
0 −0.24 0.53 0.464 1.156
5 −0.20 0.39 0.539 1.098
8 −0.19 0.14 0.768 0.975
8 −0.14 0.19 0.739 1.028
niﬁcant), payer type, baseline CCI score, physician specialty, diagnosis of essential hyper-
were not included in the GEE model.
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among privately insured patients with epilepsy in the US [12]. Our study
uncovered substantially higher average 6-month costs postbreakthrough
seizures among treatment-adherent cases ($23,821). Our study focus on
the 6-month period postbreakthrough seizure may capture a period of
heightened and costly health-care activity towards restoring control,
whichwould likely decrease over time for thosewho achieve seizure con-
trol. Inpatient care was the primary cost driver among our cases,
representing 57% of mean total costs; outpatient care was the primary
cost component for our controls (44%) as well as the general epilepsy
population (34%), demonstrating the substantial economic burden of in-
patient care associated with breakthrough seizures. The 6-month cost
among our controls ($9989) was slightly lower than the annual cost
found overall for patients with epilepsy, suggesting that our patients
with treatment-adherent breakthrough seizures and matched controls
have different demographic and clinical characteristics (required
adherence, clinically less healthy etc.) compared to the overall epilepsy
population, further supported by baseline differences between un-
matched cases and controls. Additionally, the requirement of ≥80%
AED adherence during the 6-month preindex may have resulted in a
sample with higher baseline pharmacy costs.
While we did not conduct direct comparisons of preindex and
postindex costs for patients with breakthrough seizures, the direction
of our results are consistent with the ﬁndings from Zachry et al. [17].
Costs in the 6-month pre- and postepilepsy-related emergent care
episode were compared among AED-adherent patients. Postepisode
mean all-cause costs were signiﬁcantly higher than preepisode costs
($22,813 and $14,760; 2006 USD) and similar to our respective ﬁndings
among cases ($23,821 and $13,693, respectively). Among our controls,
mean all-cause 6-month postindex costs ($9989) decreased from
mean 6-month preindex costs ($11,312), supporting other studies
which have found that costs decrease over time among patients with
epilepsy [13]. Speciﬁcally, patientswill incur costs related to initial diag-
nosis and treatment, whichwill signiﬁcantly decrease over time, partic-
ularly among those who achieve adequate seizure control through
proper AED therapy.
In our study, there was a 2.8 times increase in mean all-cause costs
between patients with 1 seizure (i.e., the breakthrough seizure) and 3+
seizures in the 6-month postbreakthrough seizure. This is consistent
with a prior study which found a 2.2-fold difference in 4-year epilepsy-
related medical costs between patients with a single seizure at onset
and those having recurrent seizures at the rate of more than one per
month, after controlling for seizure type, age, gender, and ethnicity [13].
Previous retrospective studies have looked at changes in AED thera-
py as an indicator of inadequate seizure control. Manjunath et al. found
that mean annualized, total direct health-care costs (2009 USD) were
higher in commercially insured patients with uncontrolled epilepsy
(deﬁned as ≥2 changes in AED therapy, followed by ≥1 epilepsy-
related ED visit/hospitalization within 1 year) vs. patients with well-
controlled epilepsy: $24,853 vs. $9005, and similar to our analysis, hos-
pitalizations represented the largest cost item for patients with uncon-
trolled seizures and were the main cost difference between matched
cohorts [16]. Additionally, epilepsy-related medical costs comprised
41.1% of all-cause medical costs for the patients with uncontrolled
seizures, compared to 61.1% among our cases, further demonstrating
the epilepsy-relatedmedical burden. Cramer et al. compared commercial-
ly insured patients with uncontrolled epilepsy (deﬁned as addition of an
AED to an existing regimen) and stable epilepsy and found that annual
total costs ($23,238 vs. $13,839) and epilepsy-related ($12,399 vs.
$5511) costs were higher in patients with uncontrolled epilepsy [15].
While outpatient costs were the primary cost component of total costs
(36.4% for patients with uncontrolled epilepsy and 38.9% for patients
with stable epilepsy), epilepsy-related costs comprised the majority of
total costs for patients with uncontrolled seizures (53.4% and 39.8%, re-
spectively). Chen et al. compared commercially insured patients with
POS with and without refractory epilepsy (deﬁned as use of ≥3 AEDsin a calendar year) [14]. Mean annual health-care costs (2008 USD)
for patients with treatment-refractory seizures were signiﬁcantly
higher than that for patients without treatment-refractory seizures
($33,613 vs. $19,085); however, outpatient costs comprised the major-
ity of costs ($13,431 vs. $8637). While recognizing the differences in
study design, compared to these three study ﬁndings, the 6-month
postbreakthrough seizure costs we identiﬁed are similar to the annual-
ized and annual costs of commercially insured patients with uncon-
trolled epilepsy, respectively [15,16], and 70% of the annual costs for
patients with treatment-refractory POS [17], supporting the substantial
economic impact immediately following a breakthrough seizure.
Results from this case–control study should be interpretedwith cau-
tion and in context with results from other studies, because they can
only establish associations and not cause-and-effect relationships. A
few limitations are inherent to the use of administrative claims data.
First, administrative claims databases cannot provide as much clinical
detail and accuracy as medical records as they are collected for the pur-
pose of reimbursement. Diagnoses may be recorded erroneously by
clinicians or coders or may be used as rule outs. Epilepsy diagnoses
may be recorded as a secondary diagnosis on a medical claim which is
unrelated to the patient's epilepsy status. No assumptions can be
made about the consumption of all of the medication supplied in each
prescription on time; however, if a patient consistently ﬁlls a prescrip-
tion, it is more likely that he/she is consistently consuming the medica-
tion. Pharmacy claims lack the patient's diagnosis, and some AEDs may
be used for nonepilepsy indications; however, our requirements
for both an epilepsy diagnosis and AED adherence likely rule out
nonepilepsy indications. It is also possible that a patient may choose
to go outside of his or her plan to purchase health-care services or phar-
macy, and evenAEDpharmacy, andpayout-of-pocket. However,we be-
lieve this is less likely given the eligibility requirements for patients to
have continuous health plan coverage. Nevertheless, claims data allow
for a holistic view of patient interactions with the health-care system.
A few limitations are related to the study design. First, a few signiﬁ-
cant differences remained between cases and controls following the
matching process. While these remaining differences may have inﬂated
the cost estimates among cases relative to controls, it is reﬂective of the
substantial increase in disease burden associated with the occurrence
of breakthrough seizures and the resulting difﬁculty to perfectly match
“sicker” cases to “healthier” controls. Further, while we were unable to
control for duration and severity of illness, matching on other baseline
characteristics (such as CCI) may have mitigated some of these inherent
differences. Second, the ability to identify epileptic breakthrough sei-
zures is also limited using claims databases, given the lack of conﬁrmato-
rymedical record data to understand the reason of admission. As there is
no recognized deﬁnition or speciﬁc diagnosis code for a breakthrough
seizure, we developed a standard, working deﬁnition, based on a review
of the literature and clinician input, to apply to all patients. It is important
to note that we cannot be certain that the episode of epilepsy-related
inpatient/ER care was due to a breakthrough seizure. It is possible that
the episode was related to some other destabilizing factor such as an
adverse drug side effect or a more extensive diagnostic workup. How-
ever, our analysis required a primary epilepsy diagnosis similar to the
analysis of Zachry et al. to provide greater conﬁdence that a seizure
was the cause of the emergent care episode rather than some other
event [19]. Further research may be needed to develop this deﬁnition.
It is important to note that our analysis captured only a subset of the
broader group of patients that experience breakthrough seizures, and
our approach may underestimate the burden of breakthrough seizures
for different reasons: a) we did not capture seizure events as a second-
ary diagnosis (e.g., where a traumatic event, such as fracture, is caused
by a seizure and is coded as the primary diagnosis); and b) we did
not identify patients who may have experienced seizures but did not
receive inpatient/ER care. Factors which may impact the decision to re-
ceive inpatient/ER care include history of seizures and years diagnosed,
severity of the seizure, comorbidities, general health and age, and
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been biased towards higher costs due to our breakthrough seizure def-
inition. Controls were not allowed to have an inpatient/ER admission
with a primary diagnosis of epilepsy or convulsions, and it is likely
that patients with signiﬁcant resource utilization and costs are those
who require inpatient/ER care.
Finally, the study sample may not be representative of the overall
epilepsy population. We focused our analysis on a treatment-adherent
population (that would be biased towards higher pharmacy costs), nec-
essary to provide greater conﬁdence that true breakthrough seizures
were being observed, rather than seizures due to noncompliance. In ad-
dition, our population was largely comprised of commercially insured
patients; thus, the results of our analysis may not be generalizable to
patients who are uninsured or covered by other payers. Our continuous
eligibility requirements, necessary to provide sufﬁcient visibility into
the patient's clinical history and follow-up period, exclude patients
who may have disenrolled from their plan (due to changes in employ-
ment or health status) or died during this period, thereby potentially
biasing the analysis towards a healthier sample. Our population with
continuous health plan coverage may be biased towards higher
health-care utilization and costs as a function of having coverage, com-
pared to patients without continuous health plan coverage. Further, our
results are based on an overall populationwith epilepsy. Outcomesmay
vary by individual seizure type, and a comparison of two recent publica-
tions demonstrate higher average annual costs among patients with
POS ($11,276) compared to patients overall with epilepsy ($10,258)
[12,20]. Thus, our ﬁndings may not be applicable to speciﬁc seizure
types.
5. Conclusion
While the true incidence of breakthrough seizures is unknown,
breakthrough seizures were frequent in our study. Breakthrough sei-
zures occurred among 28.4% of our study population of AED-adherent
patients. Our study provides new insights into the occurrence and
frequency of breakthrough seizures as well as their substantial health-
care resource utilization and direct cost impact among patients with
epilepsy who are treatment-adherent. These ﬁndings suggest that
more research is needed towards improving seizure control, via optimal
management and the use of effective AED therapy, which can potential-
ly lower costly hospitalizations, while improving patient outcomes and
reducing costs.
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